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Background: Oxaliplatin, the third-generation platinum compound, has evolved as one of the most important
therapeutic agents in colorectal cancer chemotherapy. The main limiting factor in oxaliplatin treatment is painful
neuropathy that is difficult to treat. This side effect has been studied for several years, but its full mechanism is still
inconclusive, and effective treatment does not exist. Data suggest that oxaliplatin’s initial neurotoxic effect is
peripheral and oxidative stress-dependent. A spinal target is also suggested in its mechanism of action. The flavonoids
rutin and quercetin have been described as cell-protecting agents because of their antioxidant, antinociceptive, and
anti-inflammatory actions. We proposed a preventive effect of these agents on oxaliplatin-induced painful peripheral
neuropathy based on their antioxidant properties.
Methods: Oxaliplatin (1 mg/kg, i.v.) was injected in male Swiss mice, twice a week (total of nine injections). The
development of sensory alterations, such as thermal and mechanical allodynia, was evaluated using the tail immersion
test in cold water (10°C) and the von Frey test. Rutin and quercetin (25-100 mg/kg, i.p.) were injected 30 min before
each oxaliplatin injection. The animals’ spinal cords were removed for histopathological and immunohistochemical
evaluation and malondialdehyde assay.
Results: Oxaliplatin significantly increased thermal and mechanical nociceptive response, effects prevented by
quercetin and rutin at all doses. Fos immunostaining in the dorsal horn of the spinal cord confirmed these results. The
oxidative stress assays mainly showed that oxaliplatin induced peroxidation in the spinal cord and that rutin and
quercetin decreased this effect. The flavonoids also decreased inducible nitric oxide synthase and nitrotyrosine
immunostaining in the dorsal horn of the spinal cord. These results suggest that nitric oxide and peroxynitrite are also
involved in the neurotoxic effect of oxaliplatin and that rutin and quercetin can inhibit their effect in the spinal cord.
We also observed the preservation of dorsal horn structure using histopathological analyses.
Conclusions: Oxaliplatin induced painful peripheral neuropathy in mice, an effect that was prevented by rutin and
quercetin. The mechanism of action of oxaliplatin appears to be, at least, partially oxidative stress-induced damage in
dorsal horn neurons, with the involvement of lipid peroxidation and protein nitrosylation.
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Platinum compounds represent an important antitumor
drug class that is widely used in the treatment of several
solid human tumors. The first synthesized molecule was
cisplatin (1854) and afterward carboplatin. Oxaliplatin is
a third-generation platinum agent with significant cyto-
toxic activity that is different from other platinum
agents, with diminished antitumoral resistance [1,2].
Today it is used in combination with 5-fluorouracil
(5-FU) and leucovorin (LV) in the FOLFOX protocol,
one of the first-line treatment regimen against metastatic
colorectal cancer [3]. The inclusion of oxaliplatin in the
FOLFOX protocol has improved response rate, time to
disease progression, and overall survival for patients with
this type of cancer [4-6].
Notwithstanding this progress in antitumor therapy,
side-effects have increased [7]. The toxicity profile, includ-
ing neutropenia, nephrotoxicity, and ototoxicity are
observed but in a significantly lower rate when compared
with the peripheral sensory neuropathy, which is the main
limiting adverse event in oxaliplatin treatment. This
neurotoxic effect appears as transient, acute, sensitive
neuropathy, the symptoms of which include perioral and
distal paresthesias, cumulative dose-related sensitive neur-
opathy [2], distal limbs paresthesias, and dysesthesias that
affect daily activities and impair the patient’s quality of life.
Joseph et al. [8] showed that oxaliplatin induced acute
neuropathy beginning with peripheral nociceptive fiber in-
jury caused by oxidative stress, and these effects are
prevented with antioxidant agents. Adequate treatment is
usually difficult to achieve and mostly disappointing be-
cause no fully effective drug yet exists. Preventive therap-
ies include ionic calcium and magnesium infusions,
vitamin E, glutathione, glutamine, and N3acetylcysteine,
with the aim of reducing neuropathic symptoms in pa-
tients who undergo antitumor therapy [9,10]. Symptom-
atic treatment is based on neuromodulating agents. Once
neuropathic pain develops, common analgesics are inef-
fective. The therapy tends to use adjuvant drugs, such as
anticonvulsants (e.g., gabapentin, carbamazepine), local
anesthetics (e.g., lidocaine), opioids (e.g., tramadol, mor-
phine), tricyclic antidepressants (e.g., amitryptyline), and
selective serotonin reuptake inhibitors [11].
Recently, new hypotheses have been proposed to ex-
plain the oxaliplatin-related neuronal injury. A neuronal
subpopulation of spinal cord dorsal ganglia appears to
be directly injured by oxaliplatin, causing neural atrophy
without any significant loss of cells [12]. In a recent
study, Joseph and co-workers [8] showed that oxaliplatin
causes pain by an action on a subset of nociceptors, the
IB4-positive DRG neurons. Oxidative stress has also
been suggested to be the direct cause of neuronal injury.
Acute thermal and mechanical hyperalgesia caused by a
single intravenous dose of oxaliplatin was inhibited byantioxidant agents, such as vitamin C and L-carnitine
[8], but this previous study was performed with only a
single oxaliplatin dose. Chronic cumulative oxaliplatin
damage has not been proven to follow the same pattern,
but this may be a key focus of future research.
The flavonoids rutin and quercetin are polyphenolics
compounds found in vegetables, fruits, herbs, leaves,
seeds [13,14], red wine, tea, coffee, beer, and several me-
dicinal plants. Rutin is a bioflavonoid and antioxidant. It
is water-soluble and converted to quercetin once it en-
ters the blood stream [15]. Several studies have found
that these flavonoids have antiinflammatory [16-18], an-
algesic [19], and antioxidant [20] effects.
Based on this background evidence on the biological
effects of flavonoid compounds and the possible
oxidative-related mechanism of neuronal injury due to
oxaliplatin injection, the present study investigated the
neuroprotective effects of rutin and quercetin on
oxaliplatin-induced neurotoxicity.
Results
Decrease in mechanical and cold nociceptive threshold
induced by oxaliplatin
Mechanical nociceptive threshold was evaluated in the
hind paws of mice that received intravenous injections of
oxaliplatin (1, 2 and 4 mg/kg) and the cold non-noxious
threshold (10°C) was evaluated using the tail immersion
test in mice that received oxaliplatin at the same doses.
The nociceptive threshold of mice was assessed, before
and after oxaliplatin injections, every week and it was ob-
served a decrease of nociceptive threshold for mechanical
and thermal stimuli. The decrease in mechanical and cold
nociceptive threshold developed by day 28 and was evalu-
ated until 56th day. Figure 1A shows the decrease of
mechanical nociceptive threshold of mice at the 49th day
after oxaliplatin first injection, which seems to be the
period in which oxaliplatin reaches the maximum of
effect. We observed a significant (p < 0.001) decrease in
the nociceptive threshold (7.19 ± 0.44, 1 mg/kg) in all the
doses tested (without no differences between them) when
compared to the control group (11.88 ± 0.44). The
Figure 1B shows the decrease of cold threshold of mice
at the 49th day after oxaliplatin first injection. A decrease
in the withdrawal threshold was observed with all the
doses, but only the dose of 1 mg/kg reached a significant
difference (16.0 ± 6.5, p < 0.001), when compared to con-
trol group (66.43 ± 5.2). For this reason we choose this
dose to perform the following experiments.
Effect of rutin and quercetin upon the mechanical
nociceptive threshold in mice subjected to oxaliplatin-
induced painful peripheral neuropathy
Mechanical nociceptive threshold was evaluated in the
hind paws of mice that received an intravenous injection
Figure 1 Decrease of mechanical and cold nociceptive threshold
induced by oxaliplatin. Each mouse received two intravenous
injections per week for 4,5 weeks, totalizing nine injections. Withdrawal
responses were determined once a week until the 49th day. Panel A:
paw withdrawal threshold of control (C, vehicle, n = 12) and treated
(oxaliplatin 1 mg/kg, 2 mg/kg and 4 mg/kg, n = 12) mice to the
electronic pressure meter (electronic von Frey) applied to the plantar
surface of the hind paw. Panel B: Tail withdrawal threshold of Control
(C, vehicle, n = 12) and treated (oxaliplatin 1 mg/kg, 2 mg/kg and
4 mg/kg, n = 12) mice to tail immersion in cold non-noxious (10°C)
water. The results are reported as the means ± SEM paw withdrawal
threshold (g) for mechanical threshold (panel A) and tail withdrawal
response (s) for the cold threshold (panel B). A significant reduction in
mechanical and thermal threshold (***p < 0.001, ANOVA followed by
Student Newman-Keuls post hoc test), was observed when compared
with the vehicle group.
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inhibited the oxaliplatin-induced decrease in mechanical
nociceptive threshold. Rutin, at all doses tested,
prevented the nociceptive response beginning on day 28,
exerting a more pronounced effect (p < 0.05) at a dose of
100 mg/kg on day 42 of treatment (10.82 ± 0.20, Figure 2A)versus oxaliplatin control group (8.61 ± 0.31). Quercetin
also inhibited at all doses tested the effect of oxaliplatin
beginning on day 21 and exerting a more pronounced
effect, at a dose of 50 mg/kg, on day 56 of treatment
(10.53 ± 0.18, Figure 2B) compared to the oxaliplatin con-
trol group (8.77 ± 0.33).
Effect of rutin and quercetin upon cold nociceptive
threshold in mice subjected to oxaliplatin-induced painful
peripheral neuropathy
The threshold for cold non-noxious (10°C) was evalu-
ated using the tail immersion test in mice that received
an intravenous injection of oxaliplatin (1 mg/kg).
Oxaliplatin increased the tail withdrawal response, and
both rutin and quercetin prevented this effect. Rutin,
only at doses of 50 and 100 mg/kg, had a significant in-
hibitory effect, reaching a maximum effect (111.50 ±
11.46, p < 0.01) at a dose of 50 mg/kg on day 42, com-
pared with the control group (17.00 ± 7.27, Figure 3A).
Quercetin, at all doses, prevented the decrease in cold
threshold (p < 0.001) beginning on day 7, with a maximal
response on day 49 at the dose of 50 mg/kg (117.16 ±
2.83) versus control group (21.00 ± 4.27, Figure 3B).
Histopathological analysis of the dorsal horn of the spinal
cord in mice subjected to oxaliplatin-induced painful
peripheral neuropathy and treated with rutin and quercetin
The histopathological analysis revealed differences be-
tween naive and oxaliplatin-treated mice. Twenty-four
hours after oxaliplatin injection, the presence of discrete
lacunar spaces was observed between neuronal cells,
suggesting nervous tissue edema. We also observed
shrinkage of the size of dorsal horn neurons, mainly
from the 14th experimental day, suggesting the atrophy
of neurons and increase in glial cell number. Both rutin
and quercetin prevented these changes, maintaining the
tissue with aspects similar to the naive group (Figure 4).
Histopathological analysis of skin harvested from the paws
of mice subjected to oxaliplatin-induced painful peripheral
neuropathy and treated with rutin and quercetin
The histopathological analysis of the paw skin of mice
injected with oxaliplatin showed the presence of little la-
cunar spaces between collagen fibers, suggesting discrete
edema of conjunctive tissue, without any other sign of
inflammation. This edema appeared to be most evident
at the first week of oxaliplatin treatment. Both rutin and
quercetin prevented the development of this event
(Figure 5).
Effects of rutin and quercetin on oxaliplatin-induced lipid
peroxidation, reflected by malondialdehyde (MDA) levels
Figure 6 shows that oxaliplatin significantly increased
(by 110.1%, p < 0.05) MDA levels in spinal cord samples
Figure 2 Antinociceptive effects of rutin and quercetin on oxaliplatin-induced mechanical nociceptive threshold decrease (von Frey).
The mice received two intravenous injections of oxaliplatin (OXL; 1 mg/kg) per week, for 4.5 weeks for a total of nine injections. Rutin (A) and
quercetin (B) were injected intraperitoneally 30 min before every OXL administration. The control group received saline instead of rutin or
quercetin. Mechanical threshold was assessed before and every 7 days after each treatment. The data points represent the mean ± SEM the paw
withdrawal response in grams (g) in six animals.*p < 0.05, **p < 0.01, ***p < 0.001 (ANOVA followed by Student Newman-Keuls post hoc test).
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(p < 0.05) by both rutin (65.1%) and quercetin (52.7%).
Immunohistochemical analysis of the dorsal horn of the
spinal cord in mice subjected to oxaliplatin-induced painful
peripheral neuropathy and treated with rutin and quercetin
The immunohistochemical analysis revealed an increase
in Fos, nitrotyrosine, and inducible nitric oxide synthase(iNOS) immunoexpression, characterized by brown-
colored cells in the dorsal horn of the spinal cord in
mice subjected to oxaliplatin-induced painful neur-
opathy (Figures 7,8,9). The Fos immunohistochemical
analysis showed intense staining (p < 0.001) of neuronal
cells, especially in the nucleus region compared with
naive animals (Figure 7B and E). Both rutin (Figure 7C)
and quercetin (Figure 7D) significantly inhibited this
Figure 3 Antinociceptive effects of rutin and quercetin on cold nociceptive threshold in oxaliplatin (OXL)-treated mice (tail immersion).
The mice received two intravenous injections of OXL (1 mg/kg) per week for 4.5 weeks for a total of nine OXL injections. Rutin (A) and quercetin
(B) were injected intraperitoneally 30 min before every OXL administration. The control group received saline instead of rutin or quercetin. The
thermal test (tail immersion test in cold water, 10°C) was conducted before and every 7 days after each treatment. The data points represent the
mean ± SEM of the reaction time in seconds after tail immersion in cold water in six animals.*p < 0.05, **p < 0.01, ***p < 0.001 (ANOVA followed
by Student Newman-Keulspost hoc test).
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histochemical analysis showed intense staining (p < 0.05;
Figure 8E) of neuronal cells, especially at the cyto-
plasmic level (Figure 8B) compared with the naive
group (Figure 8A). Quercetin (Figure 8D) but not
rutin (Figure 8C) significantly inhibited this effect (p <
0.05; Figure 8E). The iNOS immunohistochemical analysis
showed intense staining (p < 0.01; Figure 9E) of neuronal
cells, especially at the cytoplasmic level (Figure 9B)
compared with the naive group (Figure 9A). Quercetin
(Figure 9D) but not rutin (Figure 9C) significantly
inhibited this effect (p < 0.01; Figure 9E).Discussion
Painful peripheral neuropathy appears to be caused by all
platinum compounds used in cancer chemotherapy.
Among these compounds, the third-generation drug
oxaliplatin or the oxaliplatin-based regiments are one of
the first choices in the treatment of colorectal cancer, but
it is associated with the development of acute and chronic
painful neuropathy that is difficult to treat. The acute
phase affects almost every patient who receives this drug,
and the chronic effects of oxaliplatin are cumulative and
limit treatment. This side effect of oxaliplatin has been
studied for several years, but its full mechanism of action
Figure 4 Photomicrographs of the dorsal horn of the spinal cord of mice subjected to oxaliplatin (OXL)-induced neurotoxicity and
treated with rutin (RUT) or quercetin (QT). The mice received two intravenous injections of OXL (1 mg/kg) per week for 4.5 weeks for a total
of nine OXL injections. Rutin and quercetin (50 mg/kg) were injected intraperitoneally 30 min before every OXL administration. The control group
received saline instead of rutin and quercetin. The figure shows hematoxylin-eosin staining (400× magnification).
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The present study proposed preventive and therapeutic ef-
fects of the flavonoids rutin and quercetin on painful per-
ipheral neuropathy induced by oxaliplatin.Previous work by Ling et al. [21] showed that rats
treated with oxaliplatin developed painful and long-
lasting hyperalgesia in mechanical and thermal tests.
They used doses of 1, 2, and 4 mg/kg oxaliplatin with
Figure 5 Photomicrographs of the skin harvested from the paws of mice subjected to oxaliplatin (OXL)-induced neurotoxicity and
treated with rutin (RUT) or quercetin (QT). The mice received two intravenous injections of OXL (1 mg/kg) per week for 4.5 weeks for a total
of nine OXL injections. Rutin and quercetin (50 mg/kg) were injected intraperitoneally 30 min before every OXL administration. The control group
received saline instead of rutin and quercetin. The figure shows hematoxylin-eosin staining (400× magnification).
Azevedo et al. Molecular Pain 2013, 9:53 Page 7 of 14
http://www.molecularpain.com/content/9/1/53repeated intravenous administration. Based on that
study, we tested the same doses in mice, also using a
mechanical test and non-noxious cold thermal test (i.e.,
tail immersion test), and we found that oxaliplatin at1 mg/kg was the lowest effective dose which was consist-
ently capable of producing nociception in all the tests
employed in this study. In a review published by Le Bars
and colleagues [22] the influence of species and animal
Figure 6 Effect of rutin and quercetin on malondialdehyde
(MDA) levels in the spinal cord. The mice received two intravenous
injections of OXL (1 mg/kg) per week for 4.5 weeks for a total of
nine OXL injections. Rutin and quercetin (50 mg/kg) were injected
intraperitoneally 30 min before every OXL administration. The
control group received saline instead of rutin and quercetin.
Fourteen days after the first dose, a portion of the spinal cord was
collected and processed to measure MDA levels. The results are
expressed as mean ± SEM. *p < 0.05, compared with saline plus
oxaliplatin-treated group; #p < 0.05, compared with naïve (C) group
(ANOVA followed by Student Newman-Keuls post hoc test).
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the clear existence of intraspecific and interspecific vari-
ability concerning pharmacokinetics and pharmaco-
dynamics of substances in nociceptive tests. It could in
part explain the differences found between our results,
in mice, and that from Ling et al. [21], whose experi-
ments were performed in rats, in regard to the dose of
oxaliplatin used to induce peripheral neurophathy.
Therefore, we chose the 1 mg/kg dose of oxaliplatin to
investigate the effects of flavonoids on the oxaliplatin-
related nociception.
In the behavioral experiments, we showed that both
rutin and quercetin inhibited the decrease in mechanical
nociceptive threshold in the hind paws of mice subjected
to this neuropathy. This inhibitory effect was also ob-
served in cold threshold in the tail immersion test. We
found that quercetin exerted a better effect than rutin.
Fos is the protein product of the immediate-early gene
c-Fos which is found in neuronal nuclei. In most neu-
rons, Fos levels are low under basal conditions, but only
changes in afferent inputs and ⁄ or changes in external
stimuli, which induce c-fos expression, result in pheno-
typic reprogramming of the cell (Reviewed by [23]).
Therefore, Fos is a useful marker to trace the effects of
pharmacological, electrical, and physiological stimuli in
the nervous system, and it has been used to indicate
pain and neuroplasticity [24-26]. Understanding this, we
performed Fos immunostaining in dorsal horn neurons.
The results supported the hypothesis that oxaliplatin
activates nociceptive pathways because dorsal horn neu-
rons exhibited greater Fos expression in the oxaliplatin-
treated group. In addition, rutin and quercetin inhibitedFos expression, suggesting an antinociceptive effect of
these flavonoids that corroborates the behavioral results.
The histopathological changes in the dorsal horn area
were also prevented by rutin and quercetin, with a better
effect of quercetin. The flavonoids prevented the shrink-
age of neurons after 14 days and light edema formation
that occurred beginning on day 1. Edema occurred in
hind paw conjunctive tissue and was prevented by fla-
vonoid treatment. Other authors showed that another
platinum compound, cisplatin, causes neuronal nuclear
DNA damage and mitochondrial vacuolization [27-29].
Another study found morphological changes at 144 h of
cisplatin treatment, including a decrease in the size of
neuronal cells and extensive mitochondrial vacuolization
throughout the cell body, but the nuclear membrane
remained intact [29]. It is known that neurotoxicity leads
to an excessive neuronal activity leading to an increased
glutamate release. Repetitive nociceptive stimulation and
pathologic states resulting in glutamate release, there-
fore, may lead to changes in extracellular space volume
and architecture, affecting volume transmission, enhan-
cing glutamate neurotoxicity and neuronal damage [30].
In fact, we have highlighted the increased neuronal ac-
tivity in the dorsal horn of oxaliplatin injected animals
through c-Fos expression, which was prevented by rutin
and quercetin treatment.
Recent work has discussed the differences between
oxaliplatin- and paclitaxel-induced peripheral painful
neuropathy. Oxaliplatin promoted mitochondrial changes,
and chemotherapy-induced mitochondrial injury may be
the event that leads to mechanical and thermal nocicep-
tive alteration. Additionally, mitochondrial dysfunction led
to an increase in the release of free electrons from the
electron transport system and subsequent oxidative and
nitrative stress in peripheral neuronal cells [31].
Oxidative stress was also suggested by Joseph et al. as
responsible for the peripheral neuronal injury caused by
oxaliplatin. They showed that acute painful peripheral
neuropathy induced by oxaliplatin appears to be medi-
ated by an action on the IB4-positive nociceptors [8].
These authors also suggested that the nontoxic interven-
tion with antioxidants could be useful to treat the
oxaliplatin-related toxicity. The peripheral edema of the
hind paws observed in the present study may be partially
explained by this previous work. We investigated the ef-
fects of compounds with known antioxidant properties
on this effect of oxaliplatin. In our study, a remarkable
protective effect was observed. Our findings reinforce
the hypothesis that the oxidative stress event leads to
chronic neuropathy due to the oxaliplatin injection.
Recently a cellular model of oxaliplatin neurotoxicity
based on redox unbalance as mechanism of damage has
been proposed [32] and the antioxidant effect silibilin
and alpha-tocopherol [33].
Figure 7 Fos immunostaining in the dorsal horn of the spinal cord in mice subjected to oxaliplatin (OXL)-induced neurotoxicity and
treated with rutin or quercetin. The mice received two intravenous injections of OXL (1 mg/kg) per week for 4.5 weeks for a total of nine OXL
injections. Rutin or quercetin (50 mg/kg) were injected intraperitoneally 30 min before every OXL administration. The control group received
saline instead of rutin and quercetin. (A) Naive animals; (B) Oxaliplatin plus saline; (C) Oxaliplatin plus rutin (50 mg/kg); (D) Oxaliplatin plus
quercetin (50 mg/kg). 400× magnification. (E) Bars show the percentage of positive Fos staining area, mean ± SEM (n = 4). ***p < 0.001, compared with
saline plus oxaliplatin-treated group (S); ###p < 0.001, compared with naive (C) group (ANOVA followed by Student Newman-Keuls post hoc test).
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erties, in addition to their antiinflammatory [16-18] and
antinociceptive [34,35] effects. The flavonoids cyanidin
and quercetin have antioxidant potential that is four-fold
greater that of the vitamin E analog Trolox. Quercetin,
through the blockade of reactive oxygen species (ROS)
production, protects mouse hippocampal cells from
oxidative toxicity and lipid peroxidation induced by glu-
tamate. It also has an inhibitory effect on oxidative
stress-induced neurotoxicity that is exerted through
three distinct mechanisms: a direct effect on GSH me-
tabolism, an antioxidant effect, and the maintenance of
low calcium levels despite high ROS levels. Ansari et al.
[36] found that quercetin and rutin have at least two of
these properties: a direct effect on GSH metabolism and
ROS scavenger properties [36]. The unsaturated C ring
of quercetin confers an additional feature for thisflavonoid with regard to its neuroprotective effect [37].
Other authors have demonstrated that quercetin de-
creases lipid peroxidation, with a reversal in the decrease
in GSH and its dependent enzymes and a decrease in
catalase and superoxide dismutase (SOD) levels. This
antioxidant property was associated with the ability of
quercetin to significantly reverse age-related and chronic
ethanol-induced retention deficits in cognitive perform-
ance in mice [38,39].
In the present study, we verified that oxaliplatin
induced a marked lipid peroxidation. Nitrotyrosine im-
munostaining was also shown to increase in oxaliplatin-
induced neuropathy. The effect on NP-SH levels
revealed a tendency toward a decrease, but the statistical
analyses did not reveal a significant effect. Both rutin
and quercetin had antioxidant effects, reflected by inhib-
ition of the lipid peroxidation process and a decrease in
Figure 8 Nitrotyrosine immunostaining in the dorsal horn of the spinal cord of mice subjected to oxaliplatin (OXL)-induced
neurotoxicity and treated with rutin or quercetin. The mice received two intravenous injections of OXL (1 mg/kg) per week for 4.5 weeks for
a total of nine OXL injections. Rutin or quercetin (50 mg/kg) were injected intraperitoneally 30 min before every OXL administration. The control
group received saline instead of rutin and quercetin. (A) Naive animals; (B) Oxaliplatin plus saline; (C) Oxaliplatin plus rutin (50 mg/kg);
(D) Oxaliplatin plus quercetin (50 mg/kg). 400× magnification. (E) Bars show the percentage of positive nitrotyrosine staining area, mean ± SEM
(n = 4). *p < 0.05, compared with saline plus oxaliplatin-treated group (S); #p < 0.05, compared with naive (C) group (ANOVA followed by Student
Newman-Keuls post hoc test).
Azevedo et al. Molecular Pain 2013, 9:53 Page 10 of 14
http://www.molecularpain.com/content/9/1/53nitrotyrosine immunostaining in the dorsal horn of the
spinal cord.
Peroxynitrite is a powerful oxidant formed by the reac-
tion between NO and superoxide, and it is more reactive
than its precursors. Peroxynitrite reactions lead to the
formation of nitrogen dioxide and hydroxyl radicals that
directly react with target molecules, mostly tyrosine and
lipids. This can be identified in tissue by the formation
of nitrotyrosine and lipid peroxidation [40]. In a recent
publication, Kumar et al. [41] showed that peroxynitrite
and ROS, generated by excessive glutamate, were re-
sponsible for neuronal cell death in the rat cerebral cor-
tex [41]. Furthermore, these authors demonstrated that
bolus glutamate administration increased iNOS and
neuronal nitric oxide synthase (nNOS) mRNA. In theearly stage of neurotoxicity, a rapid increase in intracel-
lular Ca2+ occurs, with ROS generation and a decrease in
GSH. This leads to alterations in nNOS and iNOS mRNA
levels with the generation of NO and toxic ONOO- that
undergo chemical reactions with various substrates, such
as tyrosine nitration and lipid peroxidation [41].
Our data showed that rutin and quercetin inhibited
iNOS expression in the dorsal horn region. The protect-
ive effect on oxaliplatin neurotoxicity was at least par-
tially attributable to this action. Flavones inhibited the
production of NO [42], and quercetin and rutin
inhibited LPS-induced iNOS gene expression, reflected
by Western blot analysis, in macrophage cultures [43].
Additionally, quercetin, through its potent antioxidant
effect, prevented cisplatin-induced cytotoxicity in
Figure 9 iNOS immunostaining in the dorsal horn of the spinal cord of mice subjected to oxaliplatin (OXL)-induced neurotoxicity and
treated with rutin or quercetin. The mice received two intravenous injections of OXL (1 mg/kg) per week for 4.5 weeks for a total of nine OXL
injections. Rutin or quercetin (50 mg/kg) were injected intraperitoneally 30 min before OXL administration. The control group received saline
instead of rutin and quercetin. (A) Naive animals; (B) Oxaliplatin plus saline; (C) Oxaliplatin plus rutin (50 mg/kg); (D) Oxaliplatin plus quercetin
(50 mg/kg). 400× magnification. (E) Bars show the percentage of positive iNOS staining area, mean ± SEM (n = 4). **p < 0.01, compared with
saline plus oxaliplatin-treated group (S); ##p < 0.01, compared with naive (C) group (ANOVA followed by Student Newman-Keuls post hoc test).
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acute renal ischemia in vivo and inhibited LPS-
induced NO production [44,45].
In summary, the present study showed that oxaliplatin
induced painful peripheral neuropathy in mice, an effect
prevented by rutin and quercetin. The oxaliplatin-related
neurotoxic effect appears to occur at least partially
through oxidative stress-induced damage in dorsal horn
neurons, reflected by lipid peroxidation and protein
nitrosylation. Lipid peroxidation and tyrosine nitrosyla-
tion were prevented by flavonoid treatment. The de-
creased iNOS expression in the flavonoids-treated
groups seems to involve the inhibition of peroxynitrite-
associated neuronal damage due to the direct antioxi-
dant effect of these compounds. The present data may
lead to a better understanding of the pathogenesis ofoxaliplatin-induced neuropathy and the development of
new approaches to treat this condition, which includes
the prevention of oxidative damage.
Material and methods
Animals
The experiments were performed with male Swiss mice
(25-35 g) from our own animal facilities in accordance
with the local guidelines on the welfare of experimental
animals and with the approval of the Ethics Committee
in Animal Research of the Federal University of Ceará.
The animals were housed in temperature-controlled
rooms and received water and food ad libitum. We
followed International Association for the Study of Pain
Committee for Research and Ethical Issues guidelines
for animal research [46]. The researchers who performed
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Oxaliplatin-induced sensory neuropathy: experimental
protocol
Oxaliplatin was diluted in a 5% glucose solution (final
concentration: 1 mg/10 mL) and injected intravenously
in the lateral vein of the tail at a dose of 1 mg/kg twice a
week (on Mondays and Thursdays) with a total of nine
injections. The day oxaliplatin was first injected was
considered as experimental day 1. The dose used was
based on the work of Ling et al. [21] and adapted to our
experimental conditions. To evaluate the effect of rutin
and quercetin, the mice received an intraperitoneal injec-
tion of saline (10 mL/kg), rutin (25, 50, and 100 mg/kg) or
quercetin (25, 50, and 100 mg/kg) 30 min before every
oxaliplatin injection (1 mg/kg). The oxaliplatin, rutin and
quercetin administration stopped after the 9th injection,
but the nociceptive tests were conducted once a week
up to day 56. Biochemical, histopathology and immu-




Mechanical nociceptive threshold was assessed by stimu-
lating the hind paws with a pressure meter that con-
sisted of a handheld force transducer fitted with a
0.5 mm2 polypropylene tip (electronic von Frey Digital
Analgesymeter, Insight Instruments, São Paulo, SP,
Brazil). Briefly, in a quiet room, the mice were placed in
acrylic cages (12x20x17 cm) with wire grid floors 15–
30 min before the start of the test. A tilted mirror placed
under the grid provided a clear view of the hind paw.
The investigator was trained to apply the tip perpendicu-
larly to the central area of the hindpaw with a gradual
increase in pressure. The stimulus was automatically
discontinued and its intensity recorded when the paw
was withdrawn. The end-point was characterized by the
removal of the paw in a clear flinch response after paw
withdrawal. The animals were tested before and after
treatments. The stimulation of the paw was repeated
until the animal presented two similar measurements. If
the results were inconsistent (i.e., a marked difference in
the baseline response compared with the other animals
of the experiment), then the animal was excluded from
the study [47].
Tail immersion test
Thermal threshold was assessed using the tail immersion
test at a non-noxious temperature of 10°C [21,48]. The
tail was immersed in the water until the tail was with-
drawn. The duration of tail immersion was recorded,
with a cut-off time of 15 s. The mice were habituated tothe testing procedures and handling by the investigator
for 1 week prior to the experiment.
Histopathological analysis and immunohistochemistry
The animals were deeply anesthetized with ketamine
and xylazine (100 mg/kg and 10 mg/kg body weight, re-
spectively, i.p.) and intracardially perfused with freshly
prepared 4% paraformaldehyde in 0.1 M phosphate-
buffered saline (PBS; pH 7.4). After perfusion, the L4-5
lumbar spinal cord and hind paw skin were removed,
post-fixed in the same fixative for 1 h at 4°C, and trans-
ferred to 70% ethanol. Transversal sections of the
lumbar spinal cord were paraffin-embedded, serially sec-
tioned at a thickness of 4 μm with a microtome, and
mounted on slides. For the histopathological analysis,
the sections were deparaffinized and hydrated for
hematoxylin-eosin staining. The dorsal horn of spinal
cord was evaluated in histopathological analysis.
For immunohistochemistry, the sections were de-
paraffinized and hydrated as similar to above. Hydrated
sections were microwaved in 10 mM citrate buffer
(pH 6.1) to unmask antigenic epitopes for 15 min at
98°C and allowed to cool for 20 min at room temperature.
The sections were washed for 5 min in PBS. Afterward, the
sections were hooped with a hydrophobic pen (Dako pen®),
incubated for 15 min in peroxidase-blocking solution
(3% hydrogen peroxide), and washed for 5 min in PBS.
The sections were then incubated with primary polyclonal
goat anti-Fos, goat anti-nitrotyrosine (Millipore, USA), or
rabbit anti-iNOS antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 4°C overnight. The sections were
then washed in PBS for 5 min and incubated for 30 min at
room temperature with biotinylated goat or rabbit
secondary antibody (Santa Cruz Biotechnology). After
another wash in PBS, the tissue sections were incubated
with AB enzyme reagent (streptavidin; reagent A, Avidine;
reagent B, biotinylated horseradish peroxidase; Santa
Cruz Biotechnology) for 30 min. After a final wash in
PBS, the tissue sections were covered with chromogen
diaminobenzidine (Liquid DAB+ Substrate Chromogen
System, Dako North America, Carpinteria, CA, USA) for
2 min and then rinsed twice in distilled water for 5 min.
The sections were dehydrated, mounted in a rapid
mounting medium (Entellan, Merck, Dannstadt, Germany),
and examined with a Leica microscope coupled with
DFC232 camera (Wetzlar, Germany). After focusing
the microscope, the dorsal horn was photographed at
400× magnification. The quantification of the positive
area stained in the pictures was made differentiating
the areas (pixels) with higher color saturation associated
to immunostaining (brown). For this, we used the pro-
gram Image J - NIH. The procedure was based on color
saturation associated with positive staining for a particular
marker. The limits required for defining selected pixels
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Measuring the total area of photograph and the selected
pixels areas it was calculated the percentage of positive
stained area in each photograph. It was evaluated, at least
4 slides per group.
Malondialdehyde assay
The mice subjected to oxaliplatin-induced neuropathy
were treated with rutin and quercetin. They were then
euthanized by high-dose anesthetics, and the L4-5 lum-
bar spinal cord was removed. The tissues were immedi-
ately frozen in liquid nitrogen and stored at −80°C until
use. Lipid peroxidation was determined by measuring
MDA production using the Thiobarbituric Acid Reactive
Substances (TBARS) test [49]. Briefly, 250 μl of 10%
homogenate of tissue sample plus 1.5 ml of 1% H3PO4
and 0.5 ml of 0.6% thiobarbituric acid aqueous solution
were stirred and heated in boiling water for 45 min.
After cooling, 2 ml of n-butanol was added and stirred,
and the butanol layer was collected by centrifugation.
The optical density of the n-butanol layer was deter-
mined at 535 and 520 nm. The difference in optical
density between both determinations was calculated and
considered the thiobarbituric acid value. Malondialdehyde
concentrations are expressed as nanomoles per gram of
tissue.
Statistical analysis
The behavioral data were analyzed using one-way ana-
lysis of variance (ANOVA) followed by the Student
Newman-Keuls test to detect differences between each
treatment and control group at each time point. The
data are expressed as mean ± standard error of the mean
(SEM). The level of significance was p < 0.05.
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